SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

PRF Technologies Ltd.
Date: May 7, 2025 · CIK: 0001801834 · Accession: 0000000000-25-004834

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286941

Date
May 7, 2025
Author
Division of
Form
UPLOAD
Company
PRF Technologies Ltd.

Letter

Re: PainReform Ltd. Registration Statement on Form F-3 Filed May 2, 2025 File No. 333-286941 Dear Ehud Geller:

May 7, 2025

Ehud Geller Interim Chief Executive Officer PainReform Ltd. 65 Yigal Alon St. Tel Aviv, Israel 6744316

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 7, 2025

Ehud Geller
Interim Chief Executive Officer
PainReform Ltd.
65 Yigal Alon St.
Tel Aviv, Israel 6744316

 Re: PainReform Ltd.
 Registration Statement on Form F-3
 Filed May 2, 2025
 File No. 333-286941
Dear Ehud Geller:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jessica Dickerson at 202-551-8013 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Gary Emmanuel, Esq.
</TEXT>
</DOCUMENT>